Continued progress in XImmune AB
(Thomson Reuters ONE) -
LU Bioscience AB (LU Bio) announces positive development progression of its
portfolio company XImmune, results that attract both new capital and enforced
board competence in drug development.
XImmune has achieved the latest milestone according to the development plan with
good results. LU Bio has therefore, as lead-investor, together with Dermagen AB
and Sparbanksstiftelsen Skånes Riskkapitalstiftelse invested an additional SEK
4,4 million in the company. LU Bio now holds a 45,7% position in XImmune.
The XImmune management is enhanced by Chairman Sven Andreasson and board member
Olof Tydén. "We believe that Sven Andreasson, a lifescience profile and also
former CEO of Active Biotech together with Olof Tydén with clinical and
regulatory competence from international pharma industry will add substantial
value to XImmune" says Thomas Andersson, CEO of LU Bio. "The entrance of
Sparbanksstiftelsen Skånes Riskkapitalstiftelse as financing partner is also
very much appreciated" continues Thomas Andersson.
XImmune is developing effective treatments based on unique properties of new
classes of host defense peptides, which display potent immune-modulating and
anti-inflammatory properties. XImmune has identified previously unknown anti-
inflammatory effects of such peptides. The findings that form the basis for the
company XImmune were made by Professors Artur Schmidtchen and Martin Malmsten.
For more information, please contact:
Anki Malmborg Hager, Investment director,anki(at)lubio.se, telephone
+46 768 28 48 22
Thomas Andersson, CEO,thomas(at)lubio.se, telephone +46 70 287 00 15
About LU Bioscience AB
Lund University Bioscience AB (LU Bio) was established to help satisfy the need
to transform high-end research results and innovations into attractive business
propositions through supporting researchers. LU Bio is an early-stage investor
who provides both capital and industrial development expertise to enable a fast
and efficient development of bioscience inventions.www.lubio.se
Press Release (PDF):
http://hugin.info/141955/R/1484302/419494.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LU Bioscience via Thomson Reuters ONE
[HUG#1484302]
Unternehmensinformation / Kurzprofil:
Datum: 07.02.2011 - 09:01 Uhr
Sprache: Deutsch
News-ID 51138
Anzahl Zeichen: 2867
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 186 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Continued progress in XImmune AB"
steht unter der journalistisch-redaktionellen Verantwortung von
LU Bioscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
